Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA registry of the national heart, lung, and blood institute

The results of follow-up angiography in patients from 27 clinical centers enrolled in the PTCA Registry were analyzed to evaluate restenosis after PTCA. Of 665 patients with successful PTCA, 557 (84%) had follow-up angiography (median follow-up 188 days). Restenosis, defined as an increase of at least 30% from the immediate post-PTCA stenosis to the follow-up stenosis or a loss of at least 50% of the gain achieved at PTCA, was seen in 187 patients (33.6%). The incidence of restenosis in patients who underwent follow-up angiography was highest within the first 5 months after PTCA. Restenosis was found in 56% of patients with definite or probable angina after PTCA and in 14% of patients without angina after PTCA. Twenty-four percent of patients with restenosis did not have either definite or probable angina. Multivariate analysis selected 4 factors associated with increased rate of restenosis: male sex, PTCA of bypass graft stenosis, severity of angina before PTCA and no history of MI before PTCA.     

Cardiac arrhythmias in patients with surgical repair of Ebstein's anomaly

Preoperative, perioperative and postoperative arrhythmias in 52 consecutive patients who underwent operation for Ebstein's anomaly were reviewed. There were 25 male and 27 female patients (mean age 18 years, range 11 months to 64 years). Thirty-four patients had one or more documented arrhythmias preoperatively (18 had paroxysmal supraventricular tachycardia, 10 had paroxysmal atrial fibrillation or flutter, 13 had ventricular arrhythmia and 3 had high grade atrioventricular block). Seven patients without documented arrhythmias had a history typical of tachyarrhythmias. During the perioperative and early postoperative periods, 14 patients had atrial tachyarrhythmias and 8 had ventricular tachycardia or ventricular fibrillation. There were seven deaths between day 1 and 27 months after operation. Five of these deaths were sudden (all in male patients, aged 12 to 34 years), and four of the patients had had perioperative ventricular tachycardia or ventricular fibrillation. One patient was taking one antiarrhythmic agent and another patient was taking two at the time of sudden death. Of the 18 patients with paroxysmal supraventricular tachycardia and 9 patients with paroxysmal atrial fibrillation or flutter preoperatively who were followed up for a mean of 40 and 36 months, respectively, 22 and 33% continued to have symptomatic tachycardia. Of the 11 patients (mean age 9 years) without preoperative documentation or symptoms of arrhythmia, follow-up data were obtained (range 1 to 144 months, mean 31) in 9 patients. None died suddenly or developed symptomatic arrhythmia.     

LTD4及MK571对人结肠癌细胞SW480、Caco-2凋亡和增殖作用的体外研究

目的 观察半胱氨酰白三烯D4（LTD4）及半胱氨酰白三烯受体1拮抗剂MK571对人结肠癌细胞株SW480、Caco-2增殖和凋亡的影响.方法 MTT法检测细胞生长活性;FITC Annexin V/碘化丙啶（PI）双染流式细胞术检测细胞的凋亡率;PI染色细胞,用流式细胞仪检测细胞周期.结果 12.5 ～ 400 μg/L的LTD4对结肠癌SW480细胞有促增殖作用,且存在时效和量效依赖性;而1.6～12.5μg/L的LTD4处理24、48 h,对SW480细胞的增殖抑制作用无明显影响,作用时间延长至72 h,可促进SW480细胞的增殖.50～ 400 μg/L的LTD4对结肠癌Caco-2细胞有促增殖作用,且存在时效和量效依赖性;而1.6-50 μg/L的LTD4对结肠癌Caco-2细胞的影响与对照组相比差异无统计学意义.6.25～200 μmol/L的MK571对结肠癌SW480细胞有抑制作用,且存在时效和量效依赖性;而0.8 ～ 6.25 μmol/L的MK571对SW480细胞的影响与对照组相比无明显差异.25～ 200 μmol/L的MK571对结肠癌Caco-2细胞有抑制作用,且存在时效和量效依赖性;而0.8～ 25 μmol/L的MK571对结肠癌Caco-2细胞的影响与对照组相比差异无统计学意义.与阴性对照组相比,25 ～ 100 μg/L的LTD4对2种结肠癌SW480细胞和Caco-2细胞有促凋亡作用,且存在时效和量效依赖性;而100、200 μmol/L的MK571对2种结肠癌的凋亡无明显作用.与阴性对照组相比,25 ～ 100 μg/L的LTD4可以降低2种结肠癌细胞株G0/G1期比例,增加G2/M及S期比例;而100、200 μmol/L的MK571增加2种结肠癌细胞G0/G1期的比例,降低G2/M及S期比例.结论 LTD4具有促进人结肠癌SW480、Caco-2细胞株增殖的作用,该作用可能的作用机制是抑制凋亡、增加G2/M及S期细胞比例.MK571可抑制2种结肠癌细胞株的增殖,但对凋亡无明显影响,其抑制增殖作用的可能机制是阻滞细胞于G0/G1期.     

替米沙坦通过上调PPAR-γ促进结肠癌SW480细胞TIMP-1表达的实验研究

目的 探讨替米沙坦能否通过上调PPAR-γ促进结肠癌SW480细胞TIMP-1表达.方法 使用替米沙坦对SW480细胞进行干预.在不同时间点（0、24和72h）使用MTT法对SW480细胞活性进行测定;使用PT-PCR对在不同时间点（0、24和72h）细胞表达的TIMP-1和PPAR-γ mRNA进行测定;使用western blotting对在不同时间点（0、24和72h）细胞表达的TIMP-1和PPAR-γ蛋白进行测定.结果 替米沙坦干预后SW480细胞活性逐渐降低,明显低于对照组（均P＜0.05）,且各时间点间的细胞活性存在显著统计学差异（均P＜0.05）;不同时间点（0、24和72h） TIMP-1、PPAR-γ mRNA和蛋白的表达呈时间依赖性递增（均P＜0.05）.结论 本实验表明,替米沙坦可能是通过上调PPAR-γ的表达促进TIMP-1的合成和分泌,导致SW480细胞生长和侵袭能力的降低.     

灵芝多糖肽和小分子灵芝多糖肽抗肿瘤作用和免疫调节作用比较

目的 比较灵芝多糖肽（GLPP）和小分子灵芝多糖肽（GL-LPP3）离体抗肿瘤作用及对免疫调节作用.方法 以GLPP和GL LPP3作用于肿瘤细胞株（SW480、MCF-7、K562细胞）,以5 Fu作对照,24、48 h后收集细胞,考察其对肿瘤细胞的抑制率.建立混合淋巴细胞培养体系,以环孢素A为对照,用MTT法测定24,48,72 h细胞活性,观察GLPP和GL-1PP3对免疫的调整作用. 结果 GLPP和GLLPP3对肿瘤细胞株SW480、MCF-7、K562存活率无抑制作用;GLPP和GL-LPP3可增强淋巴细胞免疫作用. 结论 GLPP和GL-LPP3体外不能直接抑制或杀伤肿瘤细胞,可增强T淋巴细胞免疫功能.     

体外扩增CIK细胞对结肠癌SW480细胞株杀伤作用的研究

目的：观察细胞因子诱导的杀伤细胞（CIK细胞）体外增值情况,了解其扩增后杀伤结肠癌SW480细胞株最佳比例及最有效的维持时间.方法：分离健康人外周血单个核细胞在体外诱导制备成CIK细胞,计数不同培养时间的CIK细胞,采用流式细胞仪检测其表型特征.倒置显微镜下观察CIK细胞作用与SW480结肠癌细胞的形态学变化,采用HE染色、AO/EO荧光染色和MTT法检测CIK细胞对SW480结肠癌细胞株的杀伤活性.结果：CIK细胞在体外培养14 d细胞增殖倍数为（100.22±8.68）倍,培养21 d细胞增殖倍数为（300.86±10.13）倍,两者比较差异有统计学意义（P＜0.05）;培养28 d细胞增殖倍数为（305.06±5.13）倍,与培养21 d的细胞增殖倍数比较差异无统计学意义（P＞0.05）.培养21 d的CIK细胞中CD3＋、CD56＋双阳性细胞的百分比为（45.3±5.1）％,与28 d相比较差异无统计学意义（P＞0.05）,第35天细胞增殖（212.50±4.25）倍,呈下降趋势.CIK细胞对结肠癌SW480细胞株有明显的杀伤作用,最高杀伤率为（68.21±1.31）％.结论：CIK细胞具有较强的抗结肠癌细胞活性,体外培养14～21 d具有较强的抗瘤活性,此时应用较为合适.CIK细胞作用于肿瘤细胞应达到一定数量并维持一定时间,可达到较好的抗瘤活性.     

DC与CIK或LAK联合对结肠癌细胞株SW480杀伤作用的研究

[目的]研究树突状细胞(DC)联合细胞因子诱导或未诱导的杀伤细胞(CIK)或淋巴因子激活的杀伤细胞(LAK)对结肠癌细胞株SW480的杀伤活性.提供DC联合CIK或LAK治疗结肠癌的实验依据.[方法]取人外周血分离出单个核细胞(PBMNC),诱导生成DC、CIK、LAK细胞;流式细胞仪检测DC经SW480肿瘤抗原冲击后的表型变化;以CIK+DC细胞、CIK细胞、LAK+DC细胞及LAK细胞作为效应细胞,SW480为靶细胞,以15∶1、30∶1、45∶1为效靶比,LDH释放法测定细胞杀伤试验活性;ELISA检测杀伤试验中干扰素γ(IFN-γ)、白细胞介素2(IL-2)、IL-12、IL-17的分泌水平.[结果]流式细胞仪检测DC经SW480肿瘤抗原冲击后,其表面分子HLA-DR、CD40、CD80和CD86表达分别平均为90.23％、73.68％、85.96％、57.55％,与未经肿瘤抗原冲击DC比较,DC成熟的表面标志分子表达明显增加(P＜0.01).相同效靶比下,CIK+DC细胞组对SW480的杀伤作用最强,明显高于其他细胞组(P＜0.01);CIK+ DC细胞组在效靶比为45∶1时,杀伤活性最强(P＜0.01);单独CIK细胞组的杀伤活性明显高于LAK+DC细胞组(P＜0.01);LAK+ DC细胞组的杀伤活性明显高于单独LAK细胞组(P＜0.01).效靶比为45∶1时,各杀伤试验细胞组上清液中IFN-γ、IL-2、IL-12、IL-17的分泌量,CIK+DC细胞组的IFN-γ、IL-12的分泌量显著高于其他细胞组(P＜0.05);LAK+DC、单独LAK细胞组IL-2的分泌量明显高于CIK+DC、单独CIK细胞组(P＜0.05);单独CIK细胞组IFN-γ的分泌量明显高于LAK+DC、单独LAK细胞组(P＜0.05).[结论]CIK+DC细胞组对SW480的杀伤活性明显强于单独CIK、LAK+ DC组、单独LAK细胞组.其机制可能是,SW480抗原致敏的DC分泌IFN-γ、IL-12等刺激、诱导CIK细胞的活化和增殖,明显增强CIK细胞杀伤SW480的活性.     

Growth Inhibition Effect of DL-Lysine Acetylalicylate on sw480 Colon Carcinoma Cells

Objective： To investigate the effect of DL-lysine acetylsalicylate on proliferation of colon carcinoma cells line sw480. Methods： After treatment of DL-lysine acetylsalicylate, the study was performed by observing sw480 colorectal cancer cells with phase contrast microscope, making growth curve, and examining the inhibition rate of sw480 cells with MTT assay. Results： The morphology of sw480 cells showed characteristics of apoptosis, the cell growth curve showed inhibited proliferation of sw480 cells when treated with DL-lysine acetylsalicylate （P〈0.05）. The rate of inhibition was upward when the drug concentration increased. Conclusion： DL-lysine acetylsalicylate for injection can inhibit the growth of sw480 colorectal cancer cells obviously in a dose dependent manner.     

Septicemia in patients with an endocardial pacemaker.

The records of 1,235 consecutive patients treated with long-term pacing by the endocardial route between 1964 and 1977 were analyzed to determine the incidence, mechanism, course and treatment of septicemia. Septicemia developed in 12 patients (1 percent), and Staphylococcus aureus was isolated from the blood culture in 10. All patients were treated with the usual prolonged course of bactericidal drugs. Treatment was successful in only two of the seven patients whose endocardial pacing system was left in place; in three of the seven the septicemia recurred, necessitating removal of the endocardial system, and two of these patients died. In the remaining four patients the endocardial wire was promptly withdrawn, with use of a thoracotomy when necessary, and an epicardial system inserted; all of these patients survived. This is the treatment of choice.